The Effect of Lumify™ Eyedrops on Eyelid Position
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/13/2019 |
| Start Date: | July 2019 |
| End Date: | July 2021 |
| Contact: | Wendy W Lee, MD, MS |
| Email: | WLee@med.miami.edu |
| Phone: | 305-326-6434 |
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Palpebral Fissure Height
This research study designed to test if Lumify™ eyedrops temporarily raise the upper eyelid.
Lumify™ is an FDA approved medication for reducing eye redness. A similar, but stronger
product is also used to treat glaucoma. Whether or not it affects the position of the eyelids
has not been studied, but we believe that it will raise the position of the upper eyelid,
making the eye appear more open.
Lumify™ is an FDA approved medication for reducing eye redness. A similar, but stronger
product is also used to treat glaucoma. Whether or not it affects the position of the eyelids
has not been studied, but we believe that it will raise the position of the upper eyelid,
making the eye appear more open.
Inclusion Criteria:
- Adults age 18 and above able to provide informed consent to participate
- Subject with stable ocular health, defined as no ocular conditions requiring ongoing
topical therapy or recent surgical intervention
Exclusion Criteria:
- Adults unable to consent
- Prisoners
- Pregnant women.
- Known contradictions or sensitivities to study medication (brimonidine)
- Ocular surgery within the past 3 months or refractive surgery within the past six
months
- Grossly abnormal lid margins, anatomical abnormalities, previous eyelid or orbital
surgery
- Variable ptosis or eyelid position (e.g., myasthenia gravis, thyroid eye disease, or
blepharospasm)
- Significant pre-existing ptosis of any cause (defined as margin reflex distance 1 <
1mm)
- Any ocular or systemic condition that, in the opinion of the investigator, would
confound study data, interfere with the subject's study participation, or affected the
subject's safety or trial parameters
- Presence of an active ocular infection
- Prior (within 5 days of beginning study treatment) use of eye whiteners (eg,
vasoconstrictors), decongestants, antihistamines (including over the counter and
herbal topical ophthalmic medications), phenylephrine dilating drops, any other
topical ophthalmic agents
- Inability to sit comfortably for 15 - 30 minutes
We found this trial at
1
site
900 Northwest 17th Street
Miami, Florida 33136
Miami, Florida 33136
Principal Investigator: Wendy W Lee, MD, MS
Click here to add this to my saved trials
